Annals of medicine and surgery (2012) · 2025
The clinical efficacy and safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khan Muhammad Sami, Hashmi Tallal Mushtaq, Jehangir Hanzala, Akram Muhammad Faiq, Munawar Irja, Jagani Sanjna Devi, Maqsood Maham, Khalid Ayesha, Ijaz Maryam, Saeed Usman, Jafar Uzair, Ehsan Muhammad, Tuglo Lawrence Sena, Rehman Wajeeh Ur, Sabouni Mouhamed Amr, Braiteh Nabil, Yarkoni Alon, Patel Keyoor
Аннотация
OBJECTIVE: Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in patients with heart failure (HF), but the evidence of their efficacy in patients who have had an acute myocardial infarction (AMI) is still incompletely established. This review aimed to assess the safety and efficacy of SGLT2 inhibitors on cardiovascular and structural outcomes in patients who had a recent AMI, irrespective of HF.
METHODS: We searched various electronic databases, including MEDLINE (via PubMed), Embase, the Cochrane Library, and ClinicalTrials.gov, till February 2025 to retrieve randomized controlled trials comparing SGLT2 inhibitors to placebo in patients with AMI. We performed a statistical analysis on RevMan 5.4 using the random effect model.
RESULTS: Our meta-analysis included seven RCTs involving 11 302 patients compared SGLT2 inhibitors to placebo in patients with AMI. SGLT2 inhibitors significantly decreased the rate of hospitalization for HF (RR 0.73, 95% CI: 0.61-0.88) with no significant change in mortality (RR 1.05, 95% CI: 0.78-1.40), all-cause hospitalization (RR 1.00, 95% CI: 0.84-1.17), and cardiovascular death (RR 1.03, 95% CI: 0.83-1.28). The incidence of hepatic injury, ketoacidosis, hypoglycemia, or lower limb amputation remained comparable across the two groups. SGLT2 inhibitors did not cause a significant reduction in N-terminal pro-B-type natriuretic peptide (NT-pro BNP) from baseline (MD -0.28 95%, CI: -0.61-0.05) nor improved the left ventricular ejection fraction at follow-up (MD 0.62, 95%, CI -0.73-1.97) compared to the placebo.
CONCLUSION: In conclusion, while SGLT2 inhibitors show promise in reducing hospitalization for HF post-AMI, their impact on mortality and safety outcomes necessitates further investigation. This underscores the need for larger, more diverse RCTs to fully illustrate their role and timing of initiation in AMI management. An individualized approach based on risk assessment should guide their use in the post-AMI population.
METHODS: We searched various electronic databases, including MEDLINE (via PubMed), Embase, the Cochrane Library, and ClinicalTrials.gov, till February 2025 to retrieve randomized controlled trials comparing SGLT2 inhibitors to placebo in patients with AMI. We performed a statistical analysis on RevMan 5.4 using the random effect model.
RESULTS: Our meta-analysis included seven RCTs involving 11 302 patients compared SGLT2 inhibitors to placebo in patients with AMI. SGLT2 inhibitors significantly decreased the rate of hospitalization for HF (RR 0.73, 95% CI: 0.61-0.88) with no significant change in mortality (RR 1.05, 95% CI: 0.78-1.40), all-cause hospitalization (RR 1.00, 95% CI: 0.84-1.17), and cardiovascular death (RR 1.03, 95% CI: 0.83-1.28). The incidence of hepatic injury, ketoacidosis, hypoglycemia, or lower limb amputation remained comparable across the two groups. SGLT2 inhibitors did not cause a significant reduction in N-terminal pro-B-type natriuretic peptide (NT-pro BNP) from baseline (MD -0.28 95%, CI: -0.61-0.05) nor improved the left ventricular ejection fraction at follow-up (MD 0.62, 95%, CI -0.73-1.97) compared to the placebo.
CONCLUSION: In conclusion, while SGLT2 inhibitors show promise in reducing hospitalization for HF post-AMI, their impact on mortality and safety outcomes necessitates further investigation. This underscores the need for larger, more diverse RCTs to fully illustrate their role and timing of initiation in AMI management. An individualized approach based on risk assessment should guide their use in the post-AMI population.